Skip to main content
Midas Edge

Nuo Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

NUO THERAPEUTICS, INC.

TABLE OF CONTENTS

Special Note Regarding Forward-Looking Statements
Trademarks
PART I1
ITEM 1. Business1
ITEM 1A. Risk Factors7
ITEM 1B. Unresolved Staff Comments16
ITEM 1C. Cybersecurity16
ITEM 2. Properties16
ITEM 3. Legal Proceedings16
ITEM 4. Mine Safety Disclosures16
PART II17
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities17
ITEM 6. [Reserved]17
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations18
ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk21
ITEM 8. Financial Statements and Supplementary Data21
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure21
ITEM 9A. Controls and Procedures21
ITEM 9B. Other Information23
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections23
PART III24
ITEM 10. Directors, Executive Officers and Corporate Governance24
ITEM 11. Executive Compensation26
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters28
ITEM 13. Certain Relationships and Related Transactions, and Director Independence29
ITEM 14. Principal Accounting Fees and Services30
PART IV31
ITEM 15. Exhibits and Financial Statement Schedules31
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.